Results 26 - 50 from 140 for "antibiotice"
-
Antibiotice Iasi Ends 2022 With RON38.5M Net Profit, Up 29% YoY
02.27.2023
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Monday (Feb 27) that it ended 2022 with a net profit of RON38.5 million in 2022. up 28.6% versus 2021, more
-
Antibiotice Aims to Invest RON88M in 2023
02.02.2023
Romanian pharmaceutical producer Antibiotice wants to invest over RON88 million in 2023 in the Iasi production platform, from own resources and reserves, in line with its budget. more
-
Antibiotice Iasi Aims for RON580M Turnover and RON42M Profit in 2023
01.18.2023
Romanian pharmaceutical producer Antibiotice Iasi has budgeted RON580 million revenues for 2023, up 11% year-on-year and RON42 million net profit, 10% higher than in 2022. more
-
Enel X Romania To Build Solar Park For Antibiotice Iasi
12.13.2022
Enel X Romania, part of Enel X Global Retail, the advanced energy services division of Italy’s Enel Group, will build a photovoltaic (PV) park with a total installed capacity of 2.5 MW for Romanian more
-
Antibiotice Iasi Opens New Plant in Wake of EUR20M Investment
12.09.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi is opening a new plant, in the wake of a EUR20 million investment, with a 50% higher production capacity than the existing unit. more
-
Antibiotice Iasi Revenue Up 47% YoY To RON361.7M In Jan-Sept 2022
11.11.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Friday that it ended the first nine months of 2022 with sales revenue of RON361.7 million, up 47% on the more
-
Antibiotice Iasi Plans to Invest RON300M in Coming Years
10.06.2022
Romanian drug maker Antibiotice Iasi has budgeted RON300 million investments for the following years. more
-
Antibiotice Iasi Sales up 54% to RON248M in H1
08.18.2022
Romanian pharmaceutical manufacturer Antibiotice (ATB.RO) Iasi’s total revenue from sales reached RON248.1 million in the first half of 2022, up 54% on the RON161.4 million in the year-ago period, more
-
Antibiotice Wants to Develop Two Plants at Its Iasi Site
08.10.2022
Drug manufacturer Antibiotice Iasi (ATB.RO) wants to build two new factories for sterile products and sterile topical products, a total investment of RON200 million. more
-
Antibiotice Iasi Net Profit Spikes 114% YoY To RON8.6M In 1Q/2022
05.13.2022
Antibiotice Iasi (ATB.RO), the biggest Romanian-held drug maker, reported a net profit net of RON8.6 million for the first three months of 2022, up 113.7% from the year-earlier period, in line with more
-
Antibiotice Celebrates 25 Years Since Its Listing On Bucharest Stock Exchange
04.15.2022
Antibiotice (ATB), one of the most important Romanian generic drug producers, celebrates 25 years since its listing on the Bucharest Stock Exchange (BVB). The company’s shares have been trading on more
-
Antibiotice Iasi Aims for EUR1B Turnover by 2030
03.10.2022
Antibiotice Iasi, the biggest local Romanian-held drug maker, targets RON1 billion turnover by 2030, in line with its multi-annual plan, with half of this sum due to be generated by exports. more
-
Antibiotice Iasi Eyes RON448M Revenues and RON32M Net Profit in 2022
01.31.2022
Antibiotice Iasi (ATB.RO), the biggest local Romanian-held drug producer, projects total revenues worth RON448 million in 2022, up 15% on the year and net profit of RON32 million, 6% higher than in more
-
Antibiotice Iasi Wants 60% of Sales to Come From Abroad by 2028
12.10.2021
Antibiotice Iasi, the biggest local Romanian-held drug maker, aims for exports to weigh 50%-60% in turnover by 2028. more
-
SIF Oltenia Buys RON855,200 Worth of Antibiotice Shares
11.12.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-owned pharmaceutical company, on Friday notified the Bucharest Stock Exchange that regional investment fund SIF Oltenia (SIF5.RO) bought 1.5 million more
-
Antibiotice Iasi Posts 21% Increase in Revenue to RON245M in Jan-Sep
11.11.2021
The revenue of pharmaceutical company Antibiotice Iasi stood at RON245 million in January-September, an increase of 21% on the year-ago period, its report to the Bucharest Stock Exchange shows. more
-
SIF Oltenia Buys 2.7% In Antibiotice Iasi for RON10.6M
08.27.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held drug maker, on Friday reported on the Bucharest Stock Exchange that regional investment fund SIF Oltenia (SIF5) bought 18 million of its shares, more
-
Antibiotice Iasi Turnover Up 10% To RON161M, Net Profit Up Nearly 1% To RON19.3M In 1H/2021
07.26.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, reported sales of RON161.4 million in the first half of 2021, up 10.2% from the same period in 2020, per calculations by more
-
Antibiotice Iasi Earmarks RON93M for Investments in 2021
06.11.2021
Pharmaceutical producer Antibiotice budgeted RON93 million investments for 2021, RON10 million more than in 2020, mainly to develop new facilities at its plant in Iasi. more
-
Antibiotice Iasi 1Q Sales Drop 10% To RON66M, Net Profit Of RON4.03M, Close To Level In Year-Earlier Period
05.12.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, on Wednesday reported sales of RON66.1 million for the first quarter of 2021, down 10.2% on the year, and a net profit of more
-
Antibiotice Iasi Shareholders Approve RON2.22M Dividends From 2020 Profit, At 0.6% Yield
04.21.2021
Shareholders of state-run Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, on Wednesday approved the distribution of dividends worth RON2.2 million from the 2020 profit, more
-
Antibiotice Iasi Expects 7.5% Growth in Revenue to RON366M in 2021
04.15.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, has budgeted RON366.5 million revenue for 2021, an increase of 7.5% on 2020, as shown in its spending and revenue budget. more
-
SIF Oltenia Reaches 23% Ownership In Antibiotice Iasi
04.14.2021
Romanian state-owned Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, said in a stock market report on Wednesday that regional investment fund SIF Oltenia (SIF5.RO) reached more
-
Antibiotice Iasi Investments Double YoY To RON14M In 2020
03.24.2021
Romanian state-owned Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, has invested RON14 million in new product research and equipment in 2020, double compared with 2019, per more
-
Antibiotice Iasi Seeks to Distribute RON2.2M as Dividends
03.18.2021
Romanian state-owned Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, plans to distribute RON2.2 million as dividends from its 2020 profit of RON26 million profit. more